immuno oncology frontiers world miami

Immuno-Oncology Frontiers World Agenda

Loading
  1. Registration for Phacilitate Immuno-Oncology Frontiers 2018 opens
  1. Gala Welcome Drinks Reception on the Terrace
  1. Registration and networking in the IO Hub
  1. Attuning Oncology Portfolio Strategy to the Patient Response Conundrum

    Plenary
  2. Attuning Oncology Portfolio Strategy to the Patient Response Conundrum

    Plenary
  3. Attuning Oncology Portfolio Strategy to the Patient Response Conundrum

    Plenary
  4. Attuning Oncology Portfolio Strategy to the Patient Response Conundrum

    Plenary
  5. Attuning Oncology Portfolio Strategy to the Patient Response Conundrum

  6. Attuning Oncology Portfolio Strategy to the Patient Response Conundrum

    Plenary
  1. Morning coffee in the exhibition area
  1. Evaluating I-O Responders vs non-responders: paving the way to higher patient response rates

    Stream 1- I-O strategy
  2. Evaluating I-O Responders vs non-responders: paving the way to higher patient response rates

    Stream 1- I-O strategy
  3. Evaluating I-O Responders vs non-responders: paving the way to higher patient response rates

    Stream 1- I-O strategy
  4. Evaluating I-O Responders vs non-responders: paving the way to higher patient response rates

    Stream 1- I-O strategy
  5. Evaluating I-O Responders vs non-responders: paving the way to higher patient response rates

    Stream 1- I-O strategy
  1. Reprogramming the tumor microenvironment: conquering immune suppressive molecular pathways

    Stream 2- Emerging Science
  2. Reprogramming the tumor microenvironment: conquering immune suppressive molecular pathways

    Stream 2- Emerging Science
  3. Reprogramming the tumor microenvironment: conquering immune suppressive molecular pathways

    Stream 2- Emerging Science
  4. Reprogramming the tumor microenvironment: conquering immune suppressive molecular pathways

    Stream 2- Emerging Science
  5. Reprogramming the tumor microenvironment: conquering immune suppressive molecular pathways

    Stream 2- Emerging Science
  6. Reprogramming the tumor microenvironment: conquering immune suppressive molecular pathways

    Stream 2- Emerging Science
  7. Reprogramming the tumor microenvironment: conquering immune suppressive molecular pathways

    Stream 2- Emerging Science
  8. Reprogramming the tumor microenvironment: conquering immune suppressive molecular pathways

    Stream 2- Emerging Science
  1. Buffet lunch in the exhibition area
  1. Back to Basics: The road map to rationalising combination trial designs for clinical success

    Stream 1- I-O strategy
  2. Back to Basics: The road map to rationalising combination trial designs for clinical success

    Stream 1- I-O strategy
  3. Back to Basics: The road map to rationalising combination trial designs for clinical success

    Stream 1- I-O strategy
  4. Back to Basics: The road map to rationalising combination trial designs for clinical success

    Stream 1- I-O strategy
  5. Back to Basics: The road map to rationalising combination trial designs for clinical success

    Stream 1- I-O strategy
  1. Engineering the next frontier in cellular immunotherapy; looking beyond CD19

    Stream 2- Emerging Science
  2. Engineering the next frontier in cellular immunotherapy; looking beyond CD19

    Stream 2- Emerging Science
  3. Engineering the next frontier in cellular immunotherapy; looking beyond CD19

    Stream 2- Emerging Science
  4. Engineering the next frontier in cellular immunotherapy; looking beyond CD19

    Stream 2- Emerging Science
  5. Engineering the next frontier in cellular immunotherapy; looking beyond CD19

    Stream 2- Emerging Science
  6. Engineering the next frontier in cellular immunotherapy; looking beyond CD19

    Stream 2- Emerging Science
  7. Engineering the next frontier in cellular immunotherapy; looking beyond CD19

    Stream 2- Emerging Science
  8. Engineering the next frontier in cellular immunotherapy; looking beyond CD19

    Stream 2- Emerging Science
  1. Afternoon tea in the exhibition area
  1. Engaging with precision medicine: adopting the use of immuneprofiling and bioinformatics to enhance clinical development

    Stream 1- I-O strategy
  2. Engaging with precision medicine: adopting the use of immuneprofiling and bioinformatics to enhance clinical development

    Stream 1- I-O strategy
  3. Engaging with precision medicine: adopting the use of immuneprofiling and bioinformatics to enhance clinical development

    Stream 1- I-O strategy
  4. Engaging with precision medicine: adopting the use of immuneprofiling and bioinformatics to enhance clinical development

    Stream 1- I-O strategy
  5. Engaging with precision medicine: adopting the use of immuneprofiling and bioinformatics to enhance clinical development

    Stream 1- I-O strategy
  6. Engaging with precision medicine: adopting the use of immuneprofiling and bioinformatics to enhance clinical development

    Stream 1- I-O strategy
  1. The promise of bispecific antibodies: the answer to accessing solid tumors?

    Stream 2- Emerging Science
  2. The promise of bispecific antibodies: the answer to accessing solid tumors?

    Stream 2- Emerging Science
  3. The promise of bispecific antibodies: the answer to accessing solid tumors?

    Stream 2- Emerging Science
  4. The promise of bispecific antibodies: the answer to accessing solid tumors?

    Stream 2- Emerging Science
  5. The promise of bispecific antibodies: the answer to accessing solid tumors?

    Stream 2- Emerging Science
  6. The promise of bispecific antibodies: the answer to accessing solid tumors?

    Stream 2- Emerging Science
  7. The promise of bispecific antibodies: the answer to accessing solid tumors?

    Stream 2- Emerging Science
  8. The promise of bispecific antibodies: the answer to accessing solid tumors?

    Stream 2- Emerging Science
  1. Close of day 1, followed by a drinks reception
  1. Registration & breakfast in the exhibition area
  1. Morning coffee in the exhibition area
  1. PreClinical to Clinical Translation; Moving from bench to bedside with ease and surety

    Stream 1- I-O strategy
  2. Pre-clinical to Clinical Translation; Moving from bench to bedside with ease and surety

    Stream 1- I-O strategy
  3. Pre-clinical to Clinical Translation; Moving from bench to bedside with ease and surety

    Stream 1- I-O strategy
  4. Pre-clinical to Clinical Translation; Moving from bench to bedside with ease and surety

    Stream 1- I-O strategy
  5. Pre-clinical to Clinical Translation; Moving from bench to bedside with ease and surety

    Stream 1- I-O strategy
  1. Back to the future: The renaissance of cancer vaccine approaches, hope or hype?

    Stream 2- Emerging Science
  2. Back to the future: The renaissance of cancer vaccine approaches, hope or hype?

    Stream 2- Emerging Science
  3. Back to the future: The renaissance of cancer vaccine approaches, hope or hype?

    Stream 2- Emerging Science
  4. Back to the future: The renaissance of cancer vaccine approaches, hope or hype?

    Stream 2- Emerging Science
  5. Back to the future: The renaissance of cancer vaccine approaches, hope or hype?

    Stream 2- Emerging Science
  6. Back to the future: The renaissance of cancer vaccine approaches, hope or hype?

    Stream 2- Emerging Science
  7. Back to the future: The renaissance of cancer vaccine approaches, hope or hype?

    Stream 2- Emerging Science
  8. Back to the future: The renaissance of cancer vaccine approaches, hope or hype?

    Stream 2- Emerging Science
  1. buffet lunch in the exhibition area
  1. How can we further characterise the tumor microenvironment of hot vs warm vs cold tumors?

    Stream 1- I-O strategy
  2. How can we further characterise the tumor microenvironment of hot vs warm vs cold tumors?

    Stream 1- I-O strategy
  3. How can we further characterise the tumor microenvironment of hot vs warm vs cold tumors?

    Stream 1- I-O strategy
  4. How can we further characterise the tumor microenvironment of hot vs warm vs cold tumors?

    Stream 1- I-O strategy
  5. How can we further characterise the tumor microenvironment of hot vs warm vs cold tumors?

    Stream 1- I-O strategy
  1. Combination therapy clinical updates; propelling immuno-oncology dual therapies into the clinic

    Stream 2- Emerging Science
  2. Combination therapy clinical updates; propelling immuno-oncology dual therapies into the clinic

    Stream 2- Emerging Science
  3. Combination therapy clinical updates; propelling immuno-oncology dual therapies into the clinic

    Stream 2- Emerging Science
  4. Combination therapy clinical updates; propelling immuno-oncology dual therapies into the clinic

    Stream 2- Emerging Science
  5. Combination therapy clinical updates; propelling immuno-oncology dual therapies into the clinic

    Stream 2- Emerging Science
  6. Combination therapy clinical updates; propelling immuno-oncology dual therapies into the clinic

    Stream 2- Emerging Science
  7. Combination therapy clinical updates; propelling immuno-oncology dual therapies into the clinic

    Cell-based manufacturing innovation
  1. Afternoon tea in the exhibition area
  1. Immuno-Hub: Cell-based manufacturing innovation

    Cell-based manufacturing innovation
  2. Immuno-Hub: Cell-based manufacturing innovation

  3. Immuno-Hub: Cell-based manufacturing innovation

  4. Immuno-Hub: Cell-based manufacturing innovation

  5. Immuno-Hub: Cell-based manufacturing innovation

  6. Immuno-Hub: Cell-based manufacturing innovation

  1. Immuno-Hub: Overcoming the patient response challenge: Precision Medicine and biomarker solutions

  2. Immuno-Hub: Overcoming the patient response challenge: Precision Medicine and biomarker solutions

  3. Immuno-Hub: Overcoming the patient response challenge: Precision Medicine and biomarker solutions

  4. Immuno-Hub: Overcoming the patient response challenge: Precision Medicine and biomarker solutions

  5. Immuno-Hub: Overcoming the patient response challenge: Precision Medicine and biomarker solutions

  6. Immuno-Hub: Overcoming the patient response challenge: Precision Medicine and biomarker solutions

  1. Close of day 2, followed by Phacilitate Yacht Party
  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy